Today: 23 May 2026
Coinbase stock slips as bitcoin cools and Wall Street checks the fine print
7 January 2026
2 mins read

Coinbase stock slips as bitcoin cools and Wall Street checks the fine print

New York, Jan 7, 2026, 12:43 PM EST — Regular session

  • Coinbase shares fall 1.6% in midday trade as bitcoin and ether ease
  • A filing shows director Fred Wilson sold 10,000 shares under a pre-set 10b5-1 plan
  • Analyst views diverge on whether trading volumes are slowing too fast

Shares of Coinbase Global, Inc. (COIN) were down 1.6% at $246.50 on Wednesday, after trading as low as $245.48 and as high as $254.35. Bitcoin slipped 0.7% to about $91,488 and ether fell 2.4% to roughly $3,160, cooling risk appetite across crypto-linked stocks.

The U.S. crypto exchange’s stock often tracks swings in digital assets because a large share of its revenue still comes from transaction fees. When prices chop around, traders look for one thing: volume. If customers don’t trade, the fee pool dries up.

That matters now because investors are trying to work out whether the early-year bounce in crypto will translate into sustained activity, or fade into another short run. The stock has also become a liquid stand-in for broader U.S. crypto sentiment, which can turn fast when rates and growth expectations shift.

A regulatory filing on Tuesday showed Coinbase director Frederick R. Wilson sold 10,000 shares on Jan. 2 for roughly $2.34 million. The sales were made under a Rule 10b5-1 trading plan — a pre-arranged program that can let insiders trade on a set schedule — adopted on Aug. 7, 2025, the filing said.

On Monday, Goldman Sachs analyst James Yaro upgraded Coinbase to Buy and raised his price target to $303 from $294, TipRanks reported. Yaro pointed to Coinbase’s scale — including 9.5 million monthly transacting users, about $500 billion in customer assets under custody and a 48% share of the U.S. crypto exchange market — and said newer products “give it exposure to what we view as structural growth tokenization and prediction markets.” (Tokenization is using blockchain rails to represent real-world assets; prediction markets let users trade on event outcomes.) TipRanks

Not everyone is leaning in. Rosenblatt cut its price target to $325 from $470 while keeping a Buy rating, saying Coinbase’s trading volumes have “decelerated materially” and pegging fourth-quarter total trading volume at about $207 billion, down 35% from its prior estimate. TipRanks

The broader backdrop is also shifting as large banks try to package crypto exposure into mainstream products. Morgan Stanley filed with the U.S. Securities and Exchange Commission to launch ETFs tied to bitcoin and solana, and Morningstar ETF analyst Bryan Armour said: “A bank entering the crypto ETF market adds legitimacy to it, and others could follow.” (An ETF, or exchange-traded fund, is a fund that trades on an exchange like a stock.)

Outside ETFs, banks are also circling stablecoins — digital tokens pegged to a traditional currency — as settlement plumbing. Barclays bought a stake in U.S. startup Ubyx, Reuters reported, and Ubyx has previously raised money from crypto firms Coinbase and Galaxy Digital; Reuters also cited stablecoin leader Tether as circulating $187 billion in tokens.

But the stock’s downside case is still simple: fewer trades, weaker fees, and a sharper-than-expected drop in retail risk-taking. Crypto prices can move on policy headlines and leverage unwindings, and that can swamp company-specific efforts to broaden revenue.

Next up, traders are watching Friday’s U.S. monthly jobs report (Jan. 9) for clues on rates and risk appetite. Coinbase has not yet announced the date for its fourth-quarter results; Wall Street Horizon lists an unconfirmed Feb. 19 release after the close.

Stock Market Today

  • Haemonetics Q1 Earnings Beat Estimates Amid Strong Medical Devices Sector Performance
    May 22, 2026, 10:52 PM EDT. Haemonetics (NYSE:HAE) posted a robust Q1 with revenues of $346.4 million, up 4.8% year on year and exceeding analyst forecasts by 2.6%. The medical devices & supplies specialty sector outperformed expectations, with revenues beating consensus by 5.2% overall. Haemonetics shares rose 10.6% post-earnings to $58.27, reflecting investor confidence. Industry growth drivers include an aging population increasing demand for blood-related medical products and advances in digital health technology, while challenges remain from pricing pressures and regulatory demands. The sector saw steady stock performance, up 3.6% on average following earnings releases. STAAR Surgical also delivered strong results, highlighting sector momentum.

Latest articles

Dow Hits Record Close; All Eyes Turn to Holiday-Week Trading

Dow Hits Record Close; All Eyes Turn to Holiday-Week Trading

23 May 2026
The Dow closed at a record 50,579.70 on Friday, while the S&P 500 notched its eighth straight weekly gain. After-hours trading saw SPY, QQQ, DIA, and IWM all move lower. U.S. markets will be closed Monday for Memorial Day. Investors await Thursday’s inflation data.
IREN Stock Pauses as Nvidia Rally Cools Before Holiday

IREN Stock Pauses as Nvidia Rally Cools Before Holiday

23 May 2026
IREN shares fell 2.1% to $56.83 Friday, ending a two-day rally but closing the week up 7.4%. The stock’s moves follow a $3.4 billion AI cloud deal with Nvidia and a $3 billion convertible note offering. March-quarter revenue dropped to $144.8 million, with a net loss of $247.8 million. U.S. markets close Monday for Memorial Day; trading resumes Tuesday.
AXT stock reaches record; investors weigh risk to rally

AXT stock reaches record; investors weigh risk to rally

23 May 2026
AXT shares jumped 16.37% to $140.83 on Friday, hitting a 52-week high and trading above all recent analyst targets. The surge followed strong demand for AI-linked optical networking hardware and a sharp rise in indium phosphide orders. First-quarter revenue climbed to $26.9 million, with gross margin turning positive. Management forecast Q2 profitability and a backlog over $100 million.
Vedanta hits fresh 52-week high near Rs 630 on demerger trade; broker targets stretch to Rs 686
Previous Story

Vedanta hits fresh 52-week high near Rs 630 on demerger trade; broker targets stretch to Rs 686

Microchip stock slides after surprise sales forecast — traders look to Feb. 5 for proof
Next Story

Microchip stock slides after surprise sales forecast — traders look to Feb. 5 for proof

Go toTop